Monday, June 21, 2021 3:12:27 PM
Source: Edgar (US Regulatory)
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
SCHEDULE 13G
(Amendment No. )
Nascent Biotech Inc.
(Name of Issuer)
Common Shares
(Title of Class of Securities)
63108Q101
(CUSIP Number)
May 28, 2021
(Date of Event which Requires Filing of this Statement)
Check the appropriate box to designate the rule pursuant to which this Schedule is filed:
?
Rule 13d-1(b)
?
Rule 13d-1(c)
?
Rule 13d-1(d)
The information required in the remainder of this cover page shall not be deemed to be “filed” for the purpose of Section 18 of the Securities Exchange Act of 1934 (“Act”) or otherwise subject to the liabilities of that section of the Act but shall be subject to all other provisions of the Act (however, see the Notes).
SCHEDULE 13G
CUSIP NO. 63108 Q101
Page 2 of 5 Pages
1.
Name of Reporting Person I.R.S. Identification No. of above persons (entities only):
Sidney J. Lorio Jr. and Gloria Lorio, JTWROS
2.
Check the appropriate Box if a Member of a Group:
(a) ?
(b) ?
3.
SEC Use Only:
4.
Citizenship or Place of Organization:
United States
Number of
Shares
Beneficially Owned by
Each Reporting
Person With
5.
Sole Voting Power:
7,281,249
6.
Shared Voting Power:
0
7.
Sole Dispositive Power:
7,281,249
8.
Shared Dispositive Power:
0
9.
Aggregate Amount Beneficially Owned by Each Reporting Person:
7,281,249
10.
Check Box if the Aggregate Amount in Row (9) Excludes Certain Shares:
?
11.
Percent of Class Represented by Amount in Row (9):
6.80%
12.
Type of Reporting Person:
Individual
SCHEDULE 13G
CUSIP NO. 63108 Q101
Page 3 of 5 Pages
Item 1. Name of Issuer
(a)
Name of Issuer: Nascent Biotech Inc.
(b)
Address of Issuer’s Principal Executive Offices: 6330 Nancy Ridge Drive Suite 105 San Diego, CA 92121
Item 2. Name of Person Filing
(a)
Name of Person Filing: Sidney J. Lorio Jr. and Gloria Lorio, JTWROS
(b)
Address of Principal Business Office or, if None, Residence: 2116 Parkwood Drive, Bedford, TX 76021
(c)
Citizenship: USA
(d)
Title of Class of Securities: Common shares
(e)
CUSIP Number: 63108 Q101
Item 3. If this statement is filed pursuant to Rules 13d-1(b), or 13d-2(b) or (c), check whether the person filing is a:
(a)
?
Broker or dealer registered under Section 15 of the Act;
(b)
?
Bank as defined in Section 3(a)(6) of the Act;
(c)
?
Insurance company as defined in Section 3(a)(19) of the Act;
(d)
?
Investment company registered under Section 8 of the Investment Company Act;
(e)
?
An investment adviser in accordance with Rule 13d-1(b)(1)(ii)(E);
(f)
?
An employee benefit plan or endowment fund in accordance with Rule 13d-1(b)(1)(ii)(F);
(g)
?
A parent holding company or control person in accordance with Rule 13d-1(b)(1)(ii)(G);
(h)
?
A savings association as defined in Section 3(b) of the Federal Deposit Insurance Act;
(i)
?
A church plan that is excluded from the definition of an investment company under Section 3(c)(14) of the Investment Company Act;
(j)
?
Group, in accordance with Rule 13d-1(b)(1)(ii)(J).
SCHEDULE 13G
CUSIP NO. 63108 Q101
Page 4 of 5 Pages
Item 4. Ownership.
(a)
Amount Beneficially Owned: 7,281,249
(b)
Percent of Class: 6.80%
(c)
Number of shares as to which such person has:
(i)
sole power to vote or to direct the vote: 7,281,249
(ii)
shared power to vote or to direct the vote:
(iii)
sole power to dispose or to direct the disposition of: 7,281,249
(iv)
shared power to dispose or to direct the disposition of:
Item 5. Ownership of Five Percent or Less of a Class.
Item 6. Ownership of More than Five Percent on Behalf of Another Person.
Item 7. Identification and Classification of the Subsidiary Which Acquired the Security Being Reported on by the Parent Holding Company.
Item 8. Identification and Classification of Members of the Group.
Item 9. Notice of Dissolution of Group.
Item 10. Certification.
By signing below I certify that, to the best of my knowledge and belief, the securities referred to above were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect.
SCHEDULE 13G
CUSIP NO. 63108 Q101
Page 5 of 5 Pages
SIGNATURE
After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.
Sidney J. Lorio Jr. and Gloria Lorio, JTWROS
/s/ Sidney J. Lorio Jr Gloria Lorio
Recent NBIO News
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 02/27/2024 06:46:55 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 02/27/2024 06:45:51 PM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 02/14/2024 07:06:29 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 12/19/2023 01:00:24 PM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 11/09/2023 07:47:37 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 11/09/2023 07:22:19 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 11/09/2023 07:21:48 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 09/06/2023 05:54:19 PM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 08/18/2023 09:00:29 PM
- Form NT 10-Q - Notification of inability to timely file Form 10-Q or 10-QSB • Edgar (US Regulatory) • 08/14/2023 08:00:26 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 07/14/2023 06:37:08 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 07/14/2023 12:42:59 PM
- Form 10-K/A - Annual report [Section 13 and 15(d), not S-K Item 405]: [Amend] • Edgar (US Regulatory) • 07/03/2023 09:15:17 PM
- Form 10-K - Annual report [Section 13 and 15(d), not S-K Item 405] • Edgar (US Regulatory) • 06/29/2023 04:26:16 PM
FEATURED NanoViricides Reports that the Phase I NV-387 Clinical Trial is Completed Successfully and Data Lock is Expected Soon • May 2, 2024 10:07 AM
ILUS Files Form 10-K and Provides Shareholder Update • ILUS • May 2, 2024 8:52 AM
Avant Technologies Names New CEO Following Acquisition of Healthcare Technology and Data Integration Firm • AVAI • May 2, 2024 8:00 AM
Bantec Engaged in a Letter of Intent to Acquire a Small New Jersey Based Manufacturing Company • BANT • May 1, 2024 10:00 AM
Cannabix Technologies to Deliver Breath Logix Alcohol Screening Device to Australia • BLO • Apr 30, 2024 8:53 AM
Hydromer, Inc. Reports Preliminary Unaudited Financial Results for First Quarter 2024 • HYDI • Apr 29, 2024 9:10 AM